抗体药物偶联物 (ADC) 旨在携带细胞毒性有效负载并将其递送至肿瘤细胞内的特定分子靶点。多种 ADC 已获得批准，还有更多针对多种疾病类型的 ADC 正在开发中。在这篇综述中，我们将概述目前已批准和正在研究的用于实体瘤的 ADC。目前有数十种 ADC 正在进行针对多种实体瘤的临床研究评估，初步结果令人鼓舞。多种 ADC 已获得监管部门批准，用于治疗乳腺癌、非小细胞肺癌和膀胱癌等疾病。虽然有些药物在具有疾病特定适应症（例如乳腺癌）的生物标志物选择环境中获得批准，但其他药物已获得批准，无论生物标志物表达（尿路上皮癌）和生物标志物选择患者的泛癌适应症（HER2 3 表达）。各种实体瘤患者全身治疗的支柱。 ADC 具有将细胞毒性有效负载携带到特定分子受体上的优势，从而诱导更具选择性的治疗反应。优化目标抗原的选择、有效负载递送和研究反应生物标志物对于进一步扩大 ADC 在实体瘤中的治疗效果至关重要。版权所有 © 2024 Wolters Kluwer Health, Inc. 保留所有权利。

Antibody-drug conjugates (ADCs) are designed to carry cytotoxic payloads and deliver them to specific molecular targets within tumor cells. Several ADCs are already approved with many more in development across several disease types. In this review, we will provide an overview of the ADCs currently approved and those under investigation in solid tumors.Currently there are dozens of ADCs under clinical study evaluation of a variety of solid tumors, and preliminary results are promising. Multiple ADCs have received regulatory approval in disease such as breast cancer, non-small cell lung cancer, and bladder cancer. While some are approved in biomarker selected settings with disease specific indication (e.g. breast cancer), others have been approved irrespective of biomarker expression (urothelial carcinoma) and pan-cancer indications in biomarker selected patients (HER2 3+ expression).Cytotoxic chemotherapy has been the mainstay of systemic treatment for patients with various solid tumors. ADCs offer the advantage of carrying the cytotoxic payload onto a specific molecular receptor, therapy inducing a more selective response. Optimizing selection of target antigen, payload delivery and investigating biomarkers of response will be crucial for further expanding the therapeutic benefit of ADCs across solid tumors.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.